Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.76 |
| ▸ | GAA | P10253 | 4/20 | 0.76 |
| ▸ | MAPT | P10636 | 8/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | YAP1 | P46937 | 1/20 | 0.59 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | TDP2 | O95551 | 1/20 | 0.56 |
| ▸ | NSD2 | O96028 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16433503 | 0.91 | KDM4E (0.64) | KDM4EGAAMAPTKMT2AALDH1A1 | |
| SCHEMBL4160835 | 0.86 | KDM4E (1.00) | KDM4EGAAMAPTKMT2AALDH1A1 | |
| SCHEMBL4161419 | 0.76 | KDM4E (0.81) | KDM4EGAAMAPTKMT2AALDH1A1 | |
| SCHEMBL16848296 | 0.74 | KMT2A (0.81) | KDM4EGAAMAPTKMT2AALDH1A1 | |
| SCHEMBL16433497 | 0.72 | MAPT (0.76) | KDM4EGAAMAPTKMT2AALDH1A1 | |
| SCHEMBL4168854 | 0.72 | KMT2A (0.72) | KDM4EGAAMAPTKMT2AALDH1A1 | |
| SCHEMBL4151887 | 0.70 | MAPT (0.72) | KDM4EGAAMAPTKMT2AALDH1A1 | |
| SCHEMBL12164269 | 0.70 | KDM4E (0.71) | KDM4EGAAMAPTKMT2AALDH1A1 | |
| Benzamide SCHEMBL16418204 | 0.69 | MAPT (0.60) | KDM4EGAAMAPTKMT2AALDH1A1 | |
| SCHEMBL15144855 | 0.69 | PAX8 (0.62) | KDM4EGAAMAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9271960-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271960-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271960-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | PTC THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | PTC THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | PTC THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-8946444-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946444-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946444-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | PTC THERAPEUTICS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | PTC THERAPEUTICS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | PTC THERAPEUTICS, INC. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | VEGFA, FLT4, KDR | KDM4E 518/4885GAA 2618/4885MAPT 2774/4885 |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | VEGFA, FLT4, KDR | KDM4E 518/4885GAA 2618/4885MAPT 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.